net dbt
guidanc meet street lt visibl still question
walgreen ep guidanc in-lin street well worst case
fear lower bar head print qualit commentari
call lack near-term upsid driver keep us cautiou manag note
pharmaci reimburs pressur expect elev vs previou
year like driven pbm contract renew kick next year also walgreen
continu invest store optim digit initi take time
money act limit oper leverag near-term long-term
continu believ walgreen need pivot busi model
aggress contempl current healthcar retail partnership
take even greater capit resourc wba partnership model drive
increment contribut time enough lead reboot ep growth
result reiter under-perform rate maintain po
equat price-to-earnings
reduc estim lower reimburs
reduc ep ep
outlook driven continu gm pressur alreadi incorpor
on-going cost reduct busi optim healthi amount capit
deploy enough visibl return steadier ebit growth
manag highlight call
upcom event catalyst
key focu investor view gain increment comfort around
reimburs pressur guidanc releas addit commentari
around financi contribut recent struck partnership increas
labcorp roll-out increas deliveri biggest near-term opportun
well view on-going store ration final focu capit
deploy updat includ balanc vs buyback commentari
suggest less like
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
walgreen follow complet rite
aid store acquisit largest global
pharmaci nearli store us
alon compani also oper intern
pharmaci busi primarili compos
boot pharmaci unit kingdom
allianc healthcar intern wholesal
distributor pharmaceut medic
product europ walgreen headquart
under-perform rate predic
pressur competit dynam
potenti increment competit
amazon small step market core
profit dollar growth slow think limit
visibl creat challeng near-term
stock perform view range-bound
retail pharmaci intern impact challeng uk market
track cost manag program
rais annual save target least
adj oper incom mainli due retail pharmaci usa
impact share repurchas tax adj ep
growth pharmaci
comp prescript trend improv
market share
total sale due store optim
comp sale vs
comp pharmaci sale declin due lower script volum lower
uk market continu challeng
pharmaceut wholesal led emerg market uk custom contract
partnership simplifi return partnership on-demand
labcorp center open far plan
expect full year adj ep roughli flat
neg impact lower bonu pay-out
roll work capit program cost manag program see
meaning opportun reduc work capit
full year adj effect tax rate around reduc ep growth
full year share repurchas
contribut adj ep growth
expect capit expenditur top
higher tax rate impact share repurchas gener
favor tailwind
expect oper growth around
compani think reimburs
expect rel stabil wholesal busi seen strong
perform current year
msd revenu growth flat declin revenu rpi
usstrong script growth outlook continu recoveri retail
expect lsd revenu us
reimburs slightli higher previou averag
continu tough year reimburs
anyth els drive strong rx perform see benefit pilot
growth second half vs first half
conserv build cost initi execut
pilotsnot count signific flow incom build
next year
cut includ reimburs cut higher previou
script higher
awpavg mix constant basi
strategi bring specialti revenu pharmaci
develop local commun model specialti
tobacco pressur next year impact
expect continu impact next year top
much seen year
expect reimburs better longer prefer silverscript
wors averag last year
higher percentag pbm renew
posit silverscript hasnt chang
think gross profit dollar per store
come rent
offer servic lower priceinfluenc strategi
focu healthcar relationship commun locat
dont expect impact significantli
price object base ep multipl
five-year averag absolut basi around discount five-year
averag reflect view walgreen core retail pharmaci busi long-
term structur pressur must diversifi stabl busi line improv
upsid risk better expect gener save new partnership
healthcar area labcorp etc support long-
term growth addit volum econdisc/rit aid contribut
addit new partnership faster expect growth prime therapeut
relationship downsid risk po on-going price reimburs pressur
higher prescript attrit part relationship integr risk
risk amazon anoth disrupt forc enter suppli chain market
lack available/app attract capit deploy opportun
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
